Related Experiment Video

Updated: Apr 10, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.5K

Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond

Jagdeep S S Singh1, Chim C Lang1

  • 1Division of Cardiovascular and Diabetes Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.

Vascular Health and Risk Management
|June 18, 2015
PubMed

Insights

A new drug class, angiotensin receptor-neprilysin inhibitors, shows promise for heart failure treatment. These therapies target neurohormonal pathways, offering significant cardiovascular benefits and potential applications in various conditions.

Area of Science:

  • Cardiology and Pharmacology
  • Neurohormonal mechanisms in cardiovascular disease

Background:

  • Heart failure is a global health concern with limited therapeutic advancements in recent years.
  • The PARADIGM-HF trial introduced angiotensin receptor-neprilysin inhibitors, a novel drug class for heart failure.

Purpose of the Study:

  • To review the evolving understanding of neurohormonal pathways in heart failure pathophysiology.
  • To discuss the pharmacology and mechanisms of angiotensin receptor-neprilysin inhibitors.
  • To explore potential applications of this new drug class in diverse cardiovascular conditions.

Main Methods:

  • Review of literature on neurohormonal systems in heart failure.
  • Examination of the renin-angiotensin-aldosterone system.
  • Analysis of challenges in modulating the natriuretic peptide system.
  • Detailed discussion of angiotensin receptor-neprilysin inhibitor pharmacology and clinical benefits.

Main Results:

  • Significant cardiovascular benefits demonstrated by angiotensin receptor-neprilysin inhibitors.
  • Understanding of neurohormonal pathway modulation has improved heart failure treatment.
  • PARADIGM-HF trial results highlight the efficacy of this new drug class.

Conclusions:

  • Angiotensin receptor-neprilysin inhibitors represent a breakthrough in heart failure therapy.
  • This drug class offers a promising new avenue for managing heart failure and related conditions.
  • Further research may extend their application to heart failure with preserved ejection fraction, hypertension, renal impairment, and post-myocardial infarction scenarios.

Keywords:
angiotensin receptor-neprilysin inhibitorcandoxatrilheart failureheart failure with preserved ejection fractionhypertensionmyocardial infarctionnesiritideomapatrilatrenal impairment

More Related Videos

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.8K
Nitropeptide Profiling and Identification Illustrated by Angiotensin II07:31

Nitropeptide Profiling and Identification Illustrated by Angiotensin II

Published on: June 16, 2019

6.2K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.9K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.8K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
566
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.1K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.5K